FOXP2 inhibits the aggressiveness of lung cancer cells by blocking TGF&beta; signaling

Su,Wenya; Hu,Song; Zhou,Lin; Bi,Hui; Li,Zhiying

doi:10.3892/ol.2024.14361

FOXP2 inhibits the aggressiveness of lung cancer cells by blocking TGFβ signaling

Authors:
- Wenya Su
- Song Hu
- Lin Zhou
- Hui Bi
- Zhiying Li
View Affiliations

Affiliations: Department of Respiratory and Critical Care Medicine, Changzhou First People's Hospital, Changzhou, Jiangsu 213000, P.R. China, Department of Respiratory and Critical Care Medicine, Changzhou First People's Hospital, Changzhou, Jiangsu 213000, P.R. China
Published online on: March 26, 2024 https://doi.org/10.3892/ol.2024.14361
Article Number: 227
Copyright: © Su et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is associated with high morbidity and mortality rates. Forkhead box P2 (FOXP2) functions as an antitumor gene in various cancers. However, its role in lung cancer remains to be elucidated. The present study explored the potential role of FOXP2 in lung cancer. mRNA levels and protein expression were determined using RT‑qPCR and western blotting, respectively. Functional analysis was performed using the CCK‑8, Transwell and TUNEL assays. FOXP2 expression was downregulated in lung cancer. Notably, FOXP2 suppressed the proliferative, migratory and invasive abilities of lung cancer cells and promoted tumor cell apoptosis. In addition, FOXP2 blocked TGFβ signaling. However, SRI‑011381‑stimulated activation of TGFβ signaling reversed the effects of overexpressed FOXP2 and promoted the aggressiveness of lung cancer cells. FOXP2 functions as an antitumor gene in lung cancer cells. FOXP2 suppressed the malignant behavior of lung cancer by inactivating TGFβ signaling.

View Figures

View References

1	Hamann HA, Ver Hoeve ES, Carter-Harris L, Studts JL and Ostroff JS: Multilevel opportunities to address lung cancer stigma across the cancer control continuum. J Thorac Oncol. 13:1062–1075. 2018. View Article : Google Scholar : PubMed/NCBI
2	Zhuo C, Zhuang H, Gao X and Triplett PT: Lung cancer incidence in patients with schizophrenia: Meta-analysis. Br J Psychiatry. 215:704–711. 2019. View Article : Google Scholar : PubMed/NCBI
3	Nooreldeen R and Bach H: Current and Future development in lung cancer diagnosis. Int J Mol Sci. 22:86612021. View Article : Google Scholar : PubMed/NCBI
4	Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, et al: Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 394:1145–1158. 2019. View Article : Google Scholar : PubMed/NCBI
5	Yang D, Liu Y, Bai C, Wang X and Powell CA: Epidemiology of lung cancer and lung cancer screening programs in China and the United States. Cancer Lett. 468:82–87. 2020. View Article : Google Scholar : PubMed/NCBI
6	Wang M, Herbst RS and Boshoff C: Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 27:1345–1356. 2021. View Article : Google Scholar : PubMed/NCBI
7	Zugazagoitia J and Paz-Ares L: Extensive-Stage small-cell lung cancer: First-Line and second-line treatment options. J Clin Oncol. 40:671–680. 2022. View Article : Google Scholar : PubMed/NCBI
8	Nudel R and Newbury DF: Foxp2. Wiley Interdiscip Rev Cogn Sci. 4:547–560. 2013. View Article : Google Scholar : PubMed/NCBI
9	den Hoed J, Devaraju K and Fisher SE: Molecular networks of the FOXP2 transcription factor in the brain. EMBO Rep. 22:e528032021. View Article : Google Scholar : PubMed/NCBI
10	Furlong R: FOXP2 tells a cautionary tale. Nat Rev Genet. 19:592–593. 2018. View Article : Google Scholar : PubMed/NCBI
11	Nan CC, Zhang N, Cheung KCP, Zhang HD, Li W, Hong CY, Chen HS, Liu XY, Li N and Cheng L: Knockdown of lncRNA MALAT1 Alleviates LPS-Induced acute lung injury via inhibiting apoptosis through the miR-194-5p/FOXP2 Axis. Front Cell Dev Biol. 8:5868692020. View Article : Google Scholar : PubMed/NCBI
12	Ren T, Liu C, Hou J and Shan F: Hsa_circ_0043265 suppresses proliferation, metastasis, EMT and promotes apoptosis in non-small cell lung cancer through miR-25-3p/FOXP2 pathway. Onco Targets Ther. 13:3867–3880. 2020. View Article : Google Scholar : PubMed/NCBI
13	Meng F, Yang X and Xiao P: DNASE1L3 regulation by transcription factor FOXP2 affects the proliferation, migration, invasion and tube formation of lung adenocarcinoma. Exp Ther Med. 25:722022. View Article : Google Scholar : PubMed/NCBI
14	Peng D, Fu M, Wang M, Wei Y and Wei X: Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol Cancer. 21:1042022. View Article : Google Scholar : PubMed/NCBI
15	Hao Y, Baker D and Ten Dijke P: TGF-beta-mediated epithelial-mesenchymal transition and cancer metastasis. Int J Mol Sci. 20:27672019. View Article : Google Scholar : PubMed/NCBI
16	Syed V. TGF-beta signaling in cancer. J Cell Biochem. 117:1279–1287. 2016. View Article : Google Scholar : PubMed/NCBI
17	Mortezaee K, Majidpoor J and Kharazinejad E: Epithelial-mesenchymal transition in cancer stemness and heterogeneity: Updated. Med Oncol. 39:1932022. View Article : Google Scholar : PubMed/NCBI
18	Giannelli G, Koudelkova P, Dituri F and Mikulits W: Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar : PubMed/NCBI
19	Zhou JY, Zheng SR, Liu J, Shi R, Yu HL and Wei M: MiR-519d facilitates the progression and metastasis of cervical cancer through direct targeting Smad7. Cancer Cell Int. 16:212016. View Article : Google Scholar : PubMed/NCBI
20	Huang Y, Chen Z, Lu T, Bi G, Li M, Liang J, Hu Z, Zheng Y, Yin J, Xi J, et al: HIF-1alpha switches the functionality of TGF-β signaling via changing the partners of smads to drive glucose metabolic reprogramming in non-small cell lung cancer. J Exp Clin Cancer Res. 40:3982021. View Article : Google Scholar : PubMed/NCBI
21	Jie X, Fong WP, Zhou R, Zhao Y, Zhao Y, Meng R, Zhang S, Dong X, Zhang T, Yang K, et al: USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-β2 transcription. Cell Death Differ. 28:2095–2111. 2021. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Liao P, Huang WH, Cao L, Wang T and Chen LM: Low expression of FOXP2 predicts poor survival and targets caspase-1 to inhibit cell pyroptosis in colorectal cancer. J Cancer. 13:1181–1192. 2022. View Article : Google Scholar : PubMed/NCBI
24	Colak S and Ten Dijke P: Targeting TGF-β signaling in cancer. Trends Cancer. 3:56–71. 2017. View Article : Google Scholar : PubMed/NCBI
25	Lee JH and Massague J: TGF-beta in developmental and fibrogenic EMTs. Semin Cancer Biol. 86((Pt 2)): 136–145. 2022. View Article : Google Scholar : PubMed/NCBI
26	Xu P, Zhang X, Cao J, Yang J, Chen Z, Wang W, Wang S, Zhang L, Xie L, Fang L, et al: The novel role of circular RNA ST3GAL6 on blocking gastric cancer malignant behaviours through autophagy regulated by the FOXP2/MET/mTOR axis. Clin Transl Med. 12:e7072022. View Article : Google Scholar : PubMed/NCBI
27	Zhao Q, Liu C, Cui Q, Luan X, Wang Q and Zhou C: miR-190b promotes colorectal cancer progression through targeting forkhead box protein P2. Exp Ther Med. 19:79–84. 2020.PubMed/NCBI
28	Nong S, Wang Z, Wei Z, Ma L, Guan Y and Ni J: HN1L promotes stem cell-like properties by regulating TGF-β signaling pathway through targeting FOXP2 in prostate cancer. Cell Biol Int. 46:83–95. 2022. View Article : Google Scholar : PubMed/NCBI
29	Huang R, Xiang G, Duan X, Wang H, He K and Xiao J: MiR-132-3p inhibits proliferation, invasion and migration of colorectal cancer cells via down-regulating FOXP2 expression. Acta Biochim Pol. 69:371–377. 2022.PubMed/NCBI
30	Vernes SC, Newbury DF, Abrahams BS, Winchester L, Nicod J, Groszer M, Alarcón M, Oliver PL, Davies KE, Geschwind DH, et al: A functional genetic link between distinct developmental language disorders. N Engl J Med. 359:2337–2345. 2008. View Article : Google Scholar : PubMed/NCBI
31	Yang F, Xiao Z and Zhang S: FOXP2 regulates thyroid cancer cell proliferation and apoptosis via transcriptional activation of RPS6KA6. Exp Ther Med. 23:4342022. View Article : Google Scholar : PubMed/NCBI
32	Tauriello DVF, Sancho E and Batlle E: Overcoming TGFβ-mediated immune evasion in cancer. Nat Rev Cancer. 22:25–44. 2022. View Article : Google Scholar : PubMed/NCBI